Eva H. Brilstra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eva H. Brilstra has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Elena Gardella
Department of Clinical Neurophysiology, Danish Epilepsy Centre, Denmark Member of the European Reference Network, EpiCARE, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense (DK)
2 shared publications - Floortje Elisabeth Jansen
Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, Member of ERN EpiCARE University Medical Center Utrecht and Utrecht University Utrecht the Netherlands
2 shared publications - Gaetan Lesca
Department of Medical Genetics, University Hospital of Lyon, Claude Bernard University Lyon 1, Lyon, France
2 shared publications - Katrine Marie Johannesen
Department of Epilepsy Genetics and Personalized Treatment Danish Epilepsy Center Dianalund Denmark
2 shared publications - Kees P. J. Braun
Department of Child Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Member of ERN-EpiCARE, Utrecht, The Netherlands
2 shared publications - Nicolas Chatron
Genetics Department, Hospices Civils de Lyon, Lyon, France
2 shared publications
Latest Publications
- Open Access
Somatic variant analysis of resected brain tissue in epilepsy surgery patients
We studied the distribution of germline and somatic variants in epilepsy surgery patients with (suspected) malformations of cortical development (MCD) who underwent surgery between 2015 and 2020 at University Medical Center Utrecht (the Netherlands) and pooled our data with four previously published cohort studies. Tissue analysis yielded a pathogenic variant in 203 of 663 (31%) combined cases. In 126 of 379 (33%) focal cortical dysplasia (FCD) type II cases and 23 of 37 (62%) hemimegalencephaly cases, a pathogenic variant was identified, mostly involving the mTOR signaling pathway. Pathogenic variants in 10 focal epilepsy genes were found in 48 of 178 (27%) FCDI/mild MCD/mMCD with oligodendroglial hyperplasia and epilepsy cases; 36 of these (75%) were SLC35A2 variants. Six of 69 (9%) patients without a histopathological lesion had a pathogenic variant in SLC35A2 (n = 5) or DEPDC5 (n = 1). A germline variant in blood DNA was confirmed in all cases with a pathogenic variant in tissue, with a variant allele frequency (VAF) of ~50%. In seven of 114 patients (6%) with a somatic variant in tissue, mosaicism in blood was detected. More than half of pathogenic somatic variants had a VAF < 5%. Further analysis of the correlation between genetic variants and surgical outcomes will improve patient counseling and may guide postoperative treatment decisions.
Open AccessSomatic variant analysis of resected brain tissue in epilepsy surgery patients
We studied the distribution of germline and somatic variants in epilepsy surgery patients with (suspected) malformations of cortical development (MCD) who underwent surgery between 2015 and 2020 at University Medical Center Utrecht (the Netherlands) and pooled our data with four previously published cohort studies. Tissue analysis yielded a pathogenic variant in 203 of 663 (31%) combined cases. In 126 of 379 (33%) focal cortical dysplasia (FCD) type II cases and 23 of 37 (62%) hemimegalencephaly cases, a pathogenic variant was identified, mostly involving the mTOR signaling pathway. Pathogenic variants in 10 focal epilepsy genes were found in 48 of 178 (27%) FCDI/mild MCD/mMCD with oligodendroglial hyperplasia and epilepsy cases; 36 of these (75%) were SLC35A2 variants. Six of 69 (9%) patients without a histopathological lesion had a pathogenic variant in SLC35A2 (n = 5) or DEPDC5 (n = 1). A germline variant in blood DNA was confirmed in all cases with a pathogenic variant in tissue, with a variant allele frequency (VAF) of ~50%. In seven of 114 patients (6%) with a somatic variant in tissue, mosaicism in blood was detected. More than half of pathogenic somatic variants had a VAF < 5%. Further analysis of the correlation between genetic variants and surgical outcomes will improve patient counseling and may guide postoperative treatment decisions.
- Open Access
N‐of‐1 trials in epilepsy: A systematic review and lessons paving the way forward
Objective: Defined as prospective single‐patient crossover studies with repeated paired cycles of active and control intervention, N‐of‐1 trials have gained attention as an option to obtain high‐quality evidence of efficacy, particularly for patients with rare epilepsies in whom conduction of well‐powered randomized controlled trials can be challenging. The objective of this systematic review is to provide an appraisal of the literature on N‐of‐1 trials in individuals with epilepsy.Methods: We searched PubMed and Embase on January 12, 2024, for studies meeting the following criteria: prospectively planned, within‐patient, multiple‐crossover design in individuals with epilepsy and outcomes related to comorbidities. Information on design, outcome measurements, intervention, and analyses was retrieved. Risk of bias assessment was performed using the Risk of Bias in N‐of‐1 Trials (RoBiNT) scale. We highlighted methodological aspects of the N‐of‐1 trials identified and discuss future recommendations.Results: Five studies met our inclusion criteria. An additional multiple‐crossover trial that evaluated treatment effects exclusively at group level was also included because of its relevance to N‐of‐1 study methodology. The studies enrolled individuals with focal seizures, absences or cognitive impairement and electrographic discharges. Treatments included established or investigational antiseizure medications, off‐label medications, neurostimulation or lifestyle intervention. Three of the five N‐of‐1 trials reported on individual cases. The studies' strengths were the use of individualized treatment dosages and symptom‐specific patient‐reported outcomes. Limitations were related to minimal reporting of baseline characteristics and seizure burden.Significance: The trials identified by our search exemplify how the N‐of‐1 design can be applied to assess interventions in individuals with epilepsy‐related disorders. Future N‐of‐1 trials of antiseizure interventions should take into account baseline seizure frequency, should apply statistical models suited to capture seizure frequency changes reliably and make predefined interim assessments. Non‐seizure outcome measures evaluable over short periods should be considered. Tailored N‐of‐1 methodology could pave the way to evidence‐based, treatment selection for patients with rare epilepsies.
Open AccessN‐of‐1 trials in epilepsy: A systematic review and lessons paving the way forward
Objective: Defined as prospective single‐patient crossover studies with repeated paired cycles of active and control intervention, N‐of‐1 trials have gained attention as an option to obtain high‐quality evidence of efficacy, particularly for patients with rare epilepsies in whom conduction of well‐powered randomized controlled trials can be challenging. The objective of this systematic review is to provide an appraisal of the literature on N‐of‐1 trials in individuals with epilepsy.Methods: We searched PubMed and Embase on January 12, 2024, for studies meeting the following criteria: prospectively planned, within‐patient, multiple‐crossover design in individuals with epilepsy and outcomes related to comorbidities. Information on design, outcome measurements, intervention, and analyses was retrieved. Risk of bias assessment was performed using the Risk of Bias in N‐of‐1 Trials (RoBiNT) scale. We highlighted methodological aspects of the N‐of‐1 trials identified and discuss future recommendations.Results: Five studies met our inclusion criteria. An additional multiple‐crossover trial that evaluated treatment effects exclusively at group level was also included because of its relevance to N‐of‐1 study methodology. The studies enrolled individuals with focal seizures, absences or cognitive impairement and electrographic discharges. Treatments included established or investigational antiseizure medications, off‐label medications, neurostimulation or lifestyle intervention. Three of the five N‐of‐1 trials reported on individual cases. The studies' strengths were the use of individualized treatment dosages and symptom‐specific patient‐reported outcomes. Limitations were related to minimal reporting of baseline characteristics and seizure burden.Significance: The trials identified by our search exemplify how the N‐of‐1 design can be applied to assess interventions in individuals with epilepsy‐related disorders. Future N‐of‐1 trials of antiseizure interventions should take into account baseline seizure frequency, should apply statistical models suited to capture seizure frequency changes reliably and make predefined interim assessments. Non‐seizure outcome measures evaluable over short periods should be considered. Tailored N‐of‐1 methodology could pave the way to evidence‐based, treatment selection for patients with rare epilepsies.
- Open Access
- 9 September 2022
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (11) , 2351-2366
Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants
- 9 September 2022
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (11) , 2351-2366
Open AccessGenomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants
- Open Access
Structural mapping of GABRB3 variants reveals genotype-phenotype correlations
Purpose: Pathogenic variants in GABRB3 have been associated with a spectrum of phenotypes from severe developmental disorders and epileptic encephalopathies to milder epilepsy syndromes and mild intellectual disability. In the present study, we analyzed a large cohort of individuals with GABRB3 variants to deepen the phenotypic understanding and investigate genotype-phenotype correlations. Methods: Through an international collaboration, we analyzed electro-clinical data of unpublished individuals with variants in GABRB3 and we reviewed previously published cases. All missense variants were mapped onto the 3D structure of the GABRB3 subunit and clinical phenotypes associated with the different key structural domains were investigated. Results: We characterize 71 individuals with GABRB3 variants, including 22 novel subjects, expressing a wide spectrum of phenotypes. Interestingly, phenotypes correlated with structural locations of the variants. Generalized epilepsy, with a median age at onset of 10.5 months, and mild-to-moderate intellectual disability were associated with variants in the extracellular domain. Focal epilepsy with early onset (median: 2.75 months of age) and severe intellectual disability were associated with variants in the pore-lining helical transmembrane domain. Conclusion: These genotype/phenotype correlations will aid the genetic counseling and treatment of individuals affected by GABRB3 -related disorders. Future studies may reveal whether functional differences underlie the phenotypic differences. Key points: Pathogenic variants in GABRB3 cause a wide range of phenotypes Missense variants in the ECD have generalized epilepsy with later onset and non-severe ID Missense variants in the TMD have focal epilepsy with early onset and severe ID Behavioral issues are common features of GABRB3 disease Precision medicine approaches for GABRB3 disease is limited
Open AccessStructural mapping of GABRB3 variants reveals genotype-phenotype correlations
Purpose: Pathogenic variants in GABRB3 have been associated with a spectrum of phenotypes from severe developmental disorders and epileptic encephalopathies to milder epilepsy syndromes and mild intellectual disability. In the present study, we analyzed a large cohort of individuals with GABRB3 variants to deepen the phenotypic understanding and investigate genotype-phenotype correlations. Methods: Through an international collaboration, we analyzed electro-clinical data of unpublished individuals with variants in GABRB3 and we reviewed previously published cases. All missense variants were mapped onto the 3D structure of the GABRB3 subunit and clinical phenotypes associated with the different key structural domains were investigated. Results: We characterize 71 individuals with GABRB3 variants, including 22 novel subjects, expressing a wide spectrum of phenotypes. Interestingly, phenotypes correlated with structural locations of the variants. Generalized epilepsy, with a median age at onset of 10.5 months, and mild-to-moderate intellectual disability were associated with variants in the extracellular domain. Focal epilepsy with early onset (median: 2.75 months of age) and severe intellectual disability were associated with variants in the pore-lining helical transmembrane domain. Conclusion: These genotype/phenotype correlations will aid the genetic counseling and treatment of individuals affected by GABRB3 -related disorders. Future studies may reveal whether functional differences underlie the phenotypic differences. Key points: Pathogenic variants in GABRB3 cause a wide range of phenotypes Missense variants in the ECD have generalized epilepsy with later onset and non-severe ID Missense variants in the TMD have focal epilepsy with early onset and severe ID Behavioral issues are common features of GABRB3 disease Precision medicine approaches for GABRB3 disease is limited
- Open Access
- 1 May 2021
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 32, 128-135
Changes in empowerment and anxiety of patients and parents during genetic counselling for epilepsy
- 1 May 2021
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 32, 128-135
Open AccessChanges in empowerment and anxiety of patients and parents during genetic counselling for epilepsy
- Open Access
- 1 December 2019
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 5 (6) , e373
Defining and expanding the phenotype of QARS -associated developmental epileptic encephalopathy
Objective The study is aimed at widening the clinical and genetic spectrum and at assessing genotype-phenotype associations in QARS encephalopathy. Methods Through diagnostic gene panel screening in an epilepsy cohort, and recruiting through GeneMatcher and our international network, we collected 10 patients with biallelic QARS variants. In addition, we collected data on 12 patients described in the literature to further delineate the associated phenotype in a total cohort of 22 patients. Computer modeling was used to assess changes on protein folding. Results Biallelic pathogenic variants in QARS cause a triad of progressive microcephaly, moderate to severe developmental delay, and early-onset epilepsy. Microcephaly was present at birth in 65%, and in all patients at follow-up. Moderate (14%) or severe (73%) developmental delay was characteristic, with no achievement of sitting (85%), walking (86%), or talking (90%). Additional features included irritability (91%), hypertonia/spasticity (75%), hypotonia (83%), stereotypic movements (75%), and short stature (56%). Seventy-nine percent had pharmacoresistant epilepsy with mainly neonatal onset. Characteristic cranial MRI findings include early-onset progressive atrophy of cerebral cortex (89%) and cerebellum (61%), enlargement of ventricles (95%), and age-dependent delayed myelination (88%). A small subset of patients displayed a less severe phenotype. Conclusions These data revealed first genotype-phenotype associations and may serve for improved interpretation of new QARS variants and well-founded genetic counseling.
- 1 December 2019
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 5 (6) , e373
Open AccessDefining and expanding the phenotype of QARS -associated developmental epileptic encephalopathy
Objective The study is aimed at widening the clinical and genetic spectrum and at assessing genotype-phenotype associations in QARS encephalopathy. Methods Through diagnostic gene panel screening in an epilepsy cohort, and recruiting through GeneMatcher and our international network, we collected 10 patients with biallelic QARS variants. In addition, we collected data on 12 patients described in the literature to further delineate the associated phenotype in a total cohort of 22 patients. Computer modeling was used to assess changes on protein folding. Results Biallelic pathogenic variants in QARS cause a triad of progressive microcephaly, moderate to severe developmental delay, and early-onset epilepsy. Microcephaly was present at birth in 65%, and in all patients at follow-up. Moderate (14%) or severe (73%) developmental delay was characteristic, with no achievement of sitting (85%), walking (86%), or talking (90%). Additional features included irritability (91%), hypertonia/spasticity (75%), hypotonia (83%), stereotypic movements (75%), and short stature (56%). Seventy-nine percent had pharmacoresistant epilepsy with mainly neonatal onset. Characteristic cranial MRI findings include early-onset progressive atrophy of cerebral cortex (89%) and cerebellum (61%), enlargement of ventricles (95%), and age-dependent delayed myelination (88%). A small subset of patients displayed a less severe phenotype. Conclusions These data revealed first genotype-phenotype associations and may serve for improved interpretation of new QARS variants and well-founded genetic counseling.
- Open Access
- 3 June 2019
- Published by Oxford University Press (OUP) in Brain
- Vol. 142 (7) , e31
De novo SPAST mutations may cause a complex SPG4 phenotype
- 3 June 2019
- Published by Oxford University Press (OUP) in Brain
- Vol. 142 (7) , e31
Open AccessDe novo SPAST mutations may cause a complex SPG4 phenotype